IMMIX BIOPHARMA, INC. Effective Income Tax Rate Reconciliation, Tax Credit, Other, Amount
IMMIX BIOPHARMA, INC. (IMMX) reported Effective Income Tax Rate Reconciliation, Tax Credit, Other, Amount of $3.33 million for the 12-month period ending 2025-12-31, per its 10-K/A filed 2026-03-27.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationTaxCreditsOther · last filed 2026-03-27
- IMMIX BIOPHARMA, INC. effective income tax rate reconciliation, tax credit, other, amount for fiscal 2025 was $3.33M, a 98.48% increase from fiscal 2024.
- IMMIX BIOPHARMA, INC. effective income tax rate reconciliation, tax credit, other, amount for fiscal 2024 was $1.68M, a 462.40% increase from fiscal 2023.
- IMMIX BIOPHARMA, INC. effective income tax rate reconciliation, tax credit, other, amount for fiscal 2023 was $298.18K, a 65.00% increase from fiscal 2022.
- IMMIX BIOPHARMA, INC. effective income tax rate reconciliation, tax credit, other, amount for fiscal 2022 was $180.71K, a 7154.64% increase from fiscal 2021.
| Period end | Effective Income Tax Rate Reconciliation, Tax Credit, Other, Amount 12 month |
|---|---|
| 2025-12-31 | $3.33M 10-K/A · filed 2026-03-27 |
| 2024-12-31 | $1.68M 10-K/A · filed 2026-03-27 |
| 2023-12-31 | $298.18K 10-K · filed 2025-03-25 |
| 2022-12-31 | $180.71K 10-K · filed 2024-03-29 |
| 2021-12-31 | $2.49K 10-K · filed 2023-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |